阿尼卡療法 ANIK 深 滬
等待開盤 10-18 09:30:00 美东时间
9.10
+0.010
+0.11%
華盛通- 最 高9.17
- 今 開8.98
- 成交量 6.43万股
- 最 低 8.6716
- 昨 收 9.09
- 總市值 1.31亿
- 52周最高 25.00
- 市盈率 靜 --
- 換手率 0.45%
- 52周最低 7.8701
- 委 比 23.41%
- 總股本 1434.14万
- 歷史最高 75.715
- 量 比 0.99
- 振 幅 5.48%
- 歷史最低 5.24
- 每 手 1
- 風險率 4.05%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多ANI Pharmaceuticals Announces NEW DAY Clinical Trial Results to be Presented in Late-Breaking Oral Presentation at the American Academy of Ophthalmology 2025 Meeting
ANI Pharmaceuticals announced that results from the NEW DAY clinical trial of ILUVIEN for diabetic macular edema (DME) will be presented in a late-breaking oral presentation at the American Academy of Ophthalmology (AAO) 2025 Meeting. The presentation, titled "A Randomized, Active-Controlled Trial of Fluocinolone Acetonide 0.19mg Intravitreal Implant for Diabetic Macular Edema: The NEW DAY Study," will be delivered by Victor H. Gonzalez, MD, duri...
10-16 10:50
美股大行评级 | 升至450美元，瑞穗上调特斯拉目标价；富国银行上调CoreWeave至"超配"，目标价升至170美元
今日重点评级关注：Guggenheim：维持MBX Biosciences"买入"评级，目标价从44美元升至84美元；Oppenheimer：维持MBX Biosciences"跑赢大市"评级，目标价从38美元升至80美元
09-24 10:23
Barrington Research Maintains Outperform on Anika Therapeutics, Maintains $15 Price Target
Barrington Research analyst Michael Petusky maintains Anika Therapeutics (NASDAQ:ANIK) with a Outperform and maintains $15 price target.
09-23 23:01
ANI Pharmaceuticals to Present at Upcoming Investor Conferences
ANI Pharmaceuticals announced that its CEO, Nikhil Lalwani, and executive team will present at two upcoming investor conferences: the H.C. Wainwright Global Investment Conference on September 8 and the Morgan Stanley Global Healthcare Conference on September 9. Both events will be webcast live and available on the company's website for 90 days. ANI is a biopharmaceutical company focused on innovative therapeutics and sustainable growth through it...
08-25 20:30
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Replimune Group (NASDAQ:REPL) stock rose 100.5% to $7.52 during Wednes...
07-31 01:07
Anika Therapeutics shares are trading lower after the company announced the topline results from the Hyalofast trial missed its statistically significant endpoints.
Anika Therapeutics shares are trading lower after the company announced the top...
07-30 23:57
Anika outlines 10%–20% commercial channel growth for 2026–2027 amid Hyalofast FDA timeline adjustment
Earnings Call Insights: Anika Therapeutics (ANIK) Q2 2025 Management View Cheryl Renee Blanchard, President and CEO, highlighted a “meaningful quarter for Anika, including a significant clinical updat...
07-30 22:53
Anika Therapeutics Q2 Adj. EPS $(0.13) Beats $(0.17) Estimate, Sales $28.22M Beat $27.70M Estimate
Anika Therapeutics (NASDAQ:ANIK) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.17) by 23.53 percent. This is a 176.47 percent decrease over earnings of $0.17 per share
07-30 19:16
Anika Reports Topline Results from U.S. Pivotal FastTRACK Phase III Study for Hyalofast® Cartilage Repair Scaffold and Provides Program Update
Anika Therapeutics announced top-line results from its U.S. pivotal trial of Hyalofast, a hyaluronic acid scaffold used for cartilage repair. While Hyalofast showed consistent improvements over microfracture in pain and function measures, it did not meet the pre-specified co-primary endpoints for statistical significance. However, it demonstrated statistically significant improvements in key secondary endpoints and other measures aligned with pri...
07-30 11:00
ANI Pharmaceuticals Announces Results from NEW DAY Clinical Trial of ILUVIEN® for Use in Patients with Diabetic Macular Edema (DME)
The NEW DAY clinical trial compared ILUVIEN® to aflibercept for treating diabetic macular edema (DME) over 18 months. The primary endpoint of the mean number of supplemental aflibercept injections did not reach statistical significance between the ILUVIEN (2.4) and aflibercept (2.5) arms. However, a post-hoc analysis showed ILUVIEN significantly reduced the number of injections (1.8 vs. 2.5, p=0.029). ILUVIEN also met the secondary endpoint, with...
07-23 10:50
